<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>GCIG: PDL-1 in Endometrial Cancer</title>
    <meta charset="utf-8" />
    <script src="index_files/header-attrs-2.13/header-attrs.js"></script>
    <link href="index_files/remark-css-0.0.1/default.css" rel="stylesheet" />
    <script src="index_files/htmlwidgets-1.5.4/htmlwidgets.js"></script>
    <link href="index_files/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
    <script src="index_files/datatables-binding-0.23/datatables.js"></script>
    <script src="index_files/jquery-3.6.0/jquery-3.6.0.min.js"></script>
    <link href="index_files/dt-core-1.11.3/css/jquery.dataTables.min.css" rel="stylesheet" />
    <link href="index_files/dt-core-1.11.3/css/jquery.dataTables.extra.css" rel="stylesheet" />
    <script src="index_files/dt-core-1.11.3/js/jquery.dataTables.min.js"></script>
    <link href="index_files/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
    <script src="index_files/crosstalk-1.2.0/js/crosstalk.min.js"></script>
    <script type="text/x-mathjax-config">
      MathJax.Hub.Config({
        TeX: { equationNumbers: { autoNumber: "AMS" } },
      });
    </script>
    <style>
    .mjx-mrow a {
      color: black;
      pointer-events: none;
      cursor: default;
    }
    </style>
    <link rel="stylesheet" href="assets/sydney-fonts.css" type="text/css" />
    <link rel="stylesheet" href="assets/sydney.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">




class: title-slide
background-image: url("assets/title-image2.jpg")
background-position:  100% 50%
background-size: 100% 100%

# .text-shadow[.black[Statisticial conundrums in classifying patients with &lt;br&gt; PD-L1 expression in endometrial cancer]]
&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;
### .text-shadow[.white[&lt;br&gt;&lt;br&gt;&lt;br&gt; &amp;nbsp;Dr Kristy Robledo &lt;br&gt; &lt;svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;fill:blue;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M459.37 151.716c.325 4.548.325 9.097.325 13.645 0 138.72-105.583 298.558-298.558 298.558-59.452 0-114.68-17.219-161.137-47.106 8.447.974 16.568 1.299 25.34 1.299 49.055 0 94.213-16.568 130.274-44.832-46.132-.975-84.792-31.188-98.112-72.772 6.498.974 12.995 1.624 19.818 1.624 9.421 0 18.843-1.3 27.614-3.573-48.081-9.747-84.143-51.98-84.143-102.985v-1.299c13.969 7.797 30.214 12.67 47.431 13.319-28.264-18.843-46.781-51.005-46.781-87.391 0-19.492 5.197-37.36 14.294-52.954 51.655 63.675 129.3 105.258 216.365 109.807-1.624-7.797-2.599-15.918-2.599-24.04 0-57.828 46.782-104.934 104.934-104.934 30.213 0 57.502 12.67 76.67 33.137 23.715-4.548 46.456-13.32 66.599-25.34-7.798 24.366-24.366 44.833-46.132 57.827 21.117-2.273 41.584-8.122 60.426-16.243-14.292 20.791-32.161 39.308-52.628 54.253z"&gt;&lt;/path&gt;&lt;/svg&gt; @kristyrobledo]]

---
class: sydney-blue

# Overview &lt;svg viewBox="0 0 512 512" style="height:1em;display:inline-block;position:fixed;top:10;right:10;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M80 368H16a16 16 0 0 0-16 16v64a16 16 0 0 0 16 16h64a16 16 0 0 0 16-16v-64a16 16 0 0 0-16-16zm0-320H16A16 16 0 0 0 0 64v64a16 16 0 0 0 16 16h64a16 16 0 0 0 16-16V64a16 16 0 0 0-16-16zm0 160H16a16 16 0 0 0-16 16v64a16 16 0 0 0 16 16h64a16 16 0 0 0 16-16v-64a16 16 0 0 0-16-16zm416 176H176a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h320a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16zm0-320H176a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h320a16 16 0 0 0 16-16V80a16 16 0 0 0-16-16zm0 160H176a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h320a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16z"&gt;&lt;/path&gt;&lt;/svg&gt;

.font160[
- what is PD-L1?
- how is it measured?
- how reliable are the measurements?
- methods to classify "high" vs "low" expression
- what has been performed to date in EC?
]
 
???
inter-observer reliability of PD-L1

---
background-image: url("assets/pdl1.jpg")
background-position:  100% 50%
background-size: 100% 100%


.footnote[
Courtesy: [cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor)
]

???
A protein that acts as a kind of “brake” to keep the body’s immune responses under control. PD-L1 may be found on some normal cells and in higher-than-normal amounts on some types of cancer cells. When PD-L1 binds to another protein called PD-1 (a protein found on T cells), it keeps T cells from killing the PD-L1-containing cells, including the cancer cells (left panel). 

Anticancer drugs called immune checkpoint inhibitors bind to PD-L1 and block its binding to PD-1. This releases the “brakes” on the immune system and leaves T cells free to kill cancer cells (right panel).


---
background-image: url("assets/pdl1staining.JPG")
background-position:  100% 50%
background-size: 100% 100%

class: center, middle

.footnote[
Akhtar, M., Rashid, S. &amp; Al-Bozom, I.A. PD−L1 immunostaining: what pathologists need to know. Diagn Pathol 16, 94 (2021). [https://doi.org/10.1186/s13000-021-01151-x](https://doi.org/10.1186/s13000-021-01151-x)
]
--

.content-box-red[
# Doesnt sound so hard??
]

???
Case of metastatic pulmonary adenocarcinoma to the liver. B Immunohistochemical staining for tumor cells, moderate to intense staining (2+-3+) for PD-L1 TPS: 90 (DAKO 22C3 antibody)

- by pathologists
- by immunohistochemistry (IHC)
- for each immune check-point inhibitor, however, a separate immunohistochemistry (IHC) PD-L1 assay has been developed. 
---

background-image: url("assets/figassays2020.JPG")
background-position:  100% 50%
background-size: 100% 100%

.footnote[
Twomey, J.D., Zhang, B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J 23, 39 (2021). [https://doi.org/10.1208/s12248-021-00574-0](https://doi.org/10.1208/s12248-021-00574-0)
]

???

FDA approvals of PD-1/PD-L1. 
- As of December 2020, six anti-PD-1/PD-L1 mAbs have been approved with supplemental indications across 19 cancer types and two tissue-agnostic conditions. 
- Shown are the approvals for each cancer indication, for Keytruda (pembrolizumab), Opdivo (nivolumab), Libtayo (cemiplimab), Tecentriq (atezolizumab), Bavencio (avelumab), and Imfinzi (durvalumab). 
- Multiple approvals for a cancer indication within the same year are shown with only one symbol. The open symbols represent approvals without a biomarker (no BM). 
- The full symbols represent approvals that incorporate a biomarker with an associated threshold for each indication (BM), which was measured using either a central laboratory test or complementary diagnostic that was not approved as a CDx for the drug. 
- Symbols with a red outline represent approvals in which a companion diagnostic is indicated for biomarker measurement (BM + CDx). *: approval for MSI-H/dMMR colorectal cancer. PM, pleural mesothelioma; TNBC, triple-negative breast cancer; CSCC, cutaneous squamous cell carcinoma; TMB-H, tumor mutation burden high; CRC, colorectal cancer; BCG-BC, Bacillus Calmette-Guérin bladder cancer; EC, endometrial carcinoma; ESCC, esophageal squamous cell carcinoma; SCLC, small cell lung cancer; RCC, renal cell carcinoma; MCC, Merkel cell carcinoma; HCC, hepatocellular carcinoma; PMBCL, primary mediastinal large B cell lymphoma; CC, cervical cancer; GC, gastric cancer; MSI-H, microsatellite instability high; dMMR, mismatch repair-deficient; UC, urothelial carcinoma; cHL, classical Hodgkin’s lymphoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer. Information on approvals and supplemental approvals was gathered from Drugs@FDA

- In lung cancer, the 4 primary immune checkpoint inhibitors each have a different assay 
- agreement between these assays ranges from poor to high

---

# Measuring PD-L1 depends on the assay

- tumour cells (TC)
- tumor infiltrating immune cells (IC)
- presence of tumor associated immune cells (ICP) 
- tumour proportion score (TPS) - percentage of TC 
- combined proportion score (CPS)
- .... and others

???
- the percentage of PD-L1-positive tumor cells (TC)
- PD-L1 expressing tumor-infiltrating immune cells (IC) 
- The percentage of immune cells present (ICP) is reported as the percentage of tumor area occupied by any tumor-associated immune cells.
- Tumor proportion score (TPS) measured the membranous staining of tumors cells and is reported as a percentage of the total viable tumor cells.
- Combined proportion score (CPS) measures the membranous staining of tumor cells, lymphocytes, and macrophages and is reported as a percentage of the total viable tumor cells and multiplied by 100.

---
background-image: url("assets/pdl1_criteria.JPG")
background-position:  50% 50%
background-size: 60% 100%


.footnote[
Twomey, J.D., Zhang, B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J 23, 39 (2021). [https://doi.org/10.1208/s12248-021-00574-0](https://doi.org/10.1208/s12248-021-00574-0)
]

???
companion diagnostic device is required for the therapeutic product’s safe and effective use, a complementary test is performed to provide information that is clinically meaningful and will aid in the decision regarding treatment

---

background-image: url("assets/keepcalm.png")
background-position: 100% 50%
background-size: 50% 75%


.pull-left[

#  &lt;svg viewBox="0 0 576 512" style="height:1em;position:relative;display:inline-block;top:.1em;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M288 144a110.94 110.94 0 0 0-31.24 5 55.4 55.4 0 0 1 7.24 27 56 56 0 0 1-56 56 55.4 55.4 0 0 1-27-7.24A111.71 111.71 0 1 0 288 144zm284.52 97.4C518.29 135.59 410.93 64 288 64S57.68 135.64 3.48 241.41a32.35 32.35 0 0 0 0 29.19C57.71 376.41 165.07 448 288 448s230.32-71.64 284.52-177.41a32.35 32.35 0 0 0 0-29.19zM288 400c-98.65 0-189.09-55-237.93-144C98.91 167 189.34 112 288 112s189.09 55 237.93 144C477.1 345 386.66 400 288 400z"&gt;&lt;/path&gt;&lt;/svg&gt; &lt;svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M505 442.7L405.3 343c-4.5-4.5-10.6-7-17-7H372c27.6-35.3 44-79.7 44-128C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c48.3 0 92.7-16.4 128-44v16.3c0 6.4 2.5 12.5 7 17l99.7 99.7c9.4 9.4 24.6 9.4 33.9 0l28.3-28.3c9.4-9.4 9.4-24.6.1-34zM208 336c-70.7 0-128-57.2-128-128 0-70.7 57.2-128 128-128 70.7 0 128 57.2 128 128 0 70.7-57.2 128-128 128z"&gt;&lt;/path&gt;&lt;/svg&gt;

.content-box-blue[
- lots of assays

- different criteria of "high" PD-L1 for each indication/disease

- tumour heterogeneity

]
]

--

.content-box-red[.center[
# Now, what about measurement error?
]
]
???
 As described above, the use of PD-L1 as a predictive biomarker to identify those patients who are most likely to benefit from ICI treatment remains difficult due to different assays used for each therapeutic, difference in threshold cutoffs across indications, tumor heterogeneity within and across patient populations, the diversity of patients’ treatment history, and the dynamic status of the tumor microenvironment. Perhaps a single-parameter biomarker (e.g., PD-L1) may not be sufficient to accurately stratify patients for ICI therapy...

---
background-image: url("assets/jitc-2021-June-9-6--F2.large.jpg")
background-position: 100% 50%
background-size: 50% 75%

# PHAEDRA: phase II single arm trial

.pull-left[

- 71 Australian women received durvalumab  
- 36 deficient MMR and 35 proficient MMR patients
- OTR was 47% (17/36, 95% CI: 32 to 63%) in dMMR
- including 6 complete responses and 11 partial responses (PR)
- OTR was 3% in pMMR cohort (1/35, 95% CI: 1 to 15%); 1 PR
]

.footnote[
Antill Y, Kok P, Robledo K on behalf of the Australia New Zealand Gynaecological Oncology Group (ANZGOG), et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Journal for ImmunoTherapy of Cancer 2021;9:e002255. doi: 10.1136/jitc-2020-002255
]
???
based on this work, we have tumour for pdl1 staining for 67 patients
---

&lt;img src="index_files/figure-html/unnamed-chunk-1-1.png" width="95%" style="display: block; margin: auto;" /&gt;

.footnote[
(paper under review)
]

???
- the percentage of PD-L1-positive tumor cells (TC)
- PD-L1 expressing tumor-infiltrating immune cells (IC) 
- The percentage of immune cells present (ICP) is reported as the percentage of tumor area occupied by any tumor-associated immune cells.
---
# Methods for determining cutpoints 

.font140[
- clinical decision 
- use what others have used in different disease type
- minimum p-value^ 
- top left point of the ROC curve (closest to 0,1)
- Youdin index (sensitivity + specificity - 1)
- ... the list goes on, with a total of 34 methods in the `OptimalCutpoints` `R` package alone*
]
.footnote[
*López-Ratón, M., Rodríguez-Álvarez, M. X., Cadarso-Suárez, C., &amp; Gude-Sampedro, F. (2014). OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests. Journal of Statistical Software, 61(8), 1–36. [https://doi.org/10.18637/jss.v061.i08](https://doi.org/10.18637/jss.v061.i08) &lt;br&gt;
^Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994 Jun 1;86(11):829-35. doi: 10.1093/jnci/86.11.829. PMID: 8182763.
]
---
class: middle, center, sydney-blue


# Review of PD-L1 work in Endometrial Cancer

---

background-image: url("assets/Konstantinopoulos.JPG")
background-position: 50% 50%
background-size: 70% 70%

# PD-L1 in endometrial cancer (#1)


.footnote[
Konstantinopoulos PA, Luo W, et al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 Oct 20;37(30):2786-2794. doi: 10.1200/JCO.19.01021. Epub 2019 Aug 28. PMID: 31461377.
]
---

background-image: url("assets/Taylor.JPG")
background-position: 100% 50%
background-size: 50% 50%

# PD-L1 in endometrial cancer (#2)


.pull-left[

.blockquote[For patients with RCC, SCCHN, endometrial cancer, urothelial cancer and melanoma, PD-L1 status was determined using an investigational version of the PD-L1 immunohistochemistry 22C3 pharmDx assay and a provisional combined positive score, which is defined as the number of PD-L1–staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.]
]


.footnote[
Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, Stepan DE, Shumaker RC, Motzer RJ. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020 Apr 10;38(11):1154-1163. doi: 10.1200/JCO.19.01598. Epub 2020 Jan 21. Erratum in: J Clin Oncol. 2020 Aug 10;38(23):2702. PMID: 31961766; PMCID: PMC7145588.
]
---
background-image: url("assets/ott.JPG")
background-position: 0% 50%
background-size: 50% 50%

# PD-L1 in endometrial cancer (#3)

.pull-right[
&lt;br&gt;
.blockquote[
Statistical testing in a regression meta-analysis confirmed significant associations between PD-L1 CPS and both ORR (P = .018) and PFS (P = .005). The T-cell–inflamed GEP and PD-L1 CPS demonstrated a moderate, but highly statistically significant, association (r = 0.40; P &lt; .001) across 151 patients
]]


.footnote[
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13. PMID: 30557521.
]

---
background-image: url("assets/watch.png")
background-position: 50% 60%
background-size: 60% 70%

# Phaedra ?

---
# Phaedra

.font160[
- cutpoints determined as most top left point on ROC curve
- 3 scores
- each score assessed separately, then 'any' of the scores
- compared to Ventana UC algorithm and MMR status (def vs prof)
]
---
background-image: url("assets/phaedra.JPG")
background-position: 50% 40%
background-size: 80% 90%

.footnote[
TC+: tumor cells with positive staining, ICP: percentage of tumor area occupied by immune cells, IC+: percentage of tumor-associated immune cells with positive staining
*Within all patients above or below the cut point
†Urothelial cancer (UC) algorithm: TC+ ≥ 25% OR ICP&gt;1&amp; IC+ ≥ 25 OR ICP = 1 &amp; IC+ = 100
‡Optimal cut point (OC) algorithm: TC+ ≥ 1 OR ICP ≥ 10 OR IC+ ≥ 35

]
---
background-image: url("assets/phaedra_models.JPG")
background-position: 50% 100%
background-size: 70% 70%

# Phaedra: correlation with response

- most relationships with response were no longer evident after adjustment for MMR status
- no relationships with PFS/OS remained after adjustment for MMR status

???
MMR is another biomarker -&gt; is it MMR or PD-L1
other biomarkers that are not measured
account 

---
# RECAP: Endometrial cancer

<div id="htmlwidget-764e2d89589d0fd40110" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-764e2d89589d0fd40110">{"x":{"filter":"none","vertical":false,"data":[["Konstantinopoulos","Taylor","Ott","Phaedra"],["Avelumab","Lenvatinib Plus Pembrolizumab","Pembrolizumab","Durvalumab"],["22C3 assay","22C3 assay","22C3 assay","SP263 assay"],[25,23,10,67],["TPS; CPS","CPS","CPS","IC; TC; ICP"],["TPS&gt;=1; CPS &gt;?","CPS &gt;?","continuous","TC+ ≥ 1, ICP ≥ 10, IC+ ≥ 35"],["all responses in PD-L1 negative","no difference in response rates; ? difference in PFS","assessed with all other tumours (n=151); gave relationship with response and PFS","MMR status appears stronger"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th>Trial<\/th>\n      <th>ICI<\/th>\n      <th>Assay<\/th>\n      <th>Patients<\/th>\n      <th>Score<\/th>\n      <th>Cutpoint<\/th>\n      <th>Relationship with outcomes<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"Trial":["Konstantinopoulos","Taylor","Ott","Phaedra"],"ICI":["Avelumab","Lenvatinib Plus Pembrolizumab","Pembrolizumab","Durvalumab"],"Assay":["22C3 assay","22C3 assay","22C3 assay","SP263 assay"],"Patients":[25,23,10,67],"Score":["TPS; CPS","CPS","CPS","IC; TC; ICP"],"Cutpoint":["TPS>=1; CPS >?","CPS >?","continuous","TC+ ≥ 1, ICP ≥ 10, IC+ ≥ 35"],"Relationship with outcomes":["all responses in PD-L1 negative","no difference in response rates; ? difference in PFS","assessed with all other tumours (n=151); gave relationship with response and PFS","MMR status appears stronger"],"columnDefs":[{"className":"dt-right","targets":3}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data, displayNum, displayIndex, dataIndex) {\nvar value=data[6]; $(this.api().cell(row, 6).node()).css({'font-size':'70%'});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
???
- Konstantinopoulos: Avelumab; 22C3 assay; n=25; TPS&gt;=1 plus another analysis by CPS &gt; ?; all responses in PD-L1 NEGATIVE

- Taylor: Lenvatinib Plus Pembrolizumab; 22C3 assay; n=23; CPS &gt; ?, no difference in response rates; ? difference in PFS

- Ott: Pembrolizumab; 22C3 assay; n=10 with PD-L1 data; continuous CPS; with all other tumours gave relationship with response and PFS

- PHAEDRA: durvalumab; SP263 assay; n=67; MMR status has stronger relationship with PD-L1?

---
class: sydney-blue

# PD-L1 take home messages/questions

.font120[
* different assays &amp; cutpoints, giving ?correlation with outcome
]
--
.font120[
* consider inter-observer reliability (both across and within assays)
]
--
.font120[
* importance of classification of PD-L1 status not by apriori... by statistical methods at trial completion? which of the 34 methods? adjust for the multiple comparisons if minimum p-value? 
]
--
.font120[
* PD-L1  - possibly not as strong as seen in other disease types?
]
--
.font120[
* need to also measure MMR

* combine with MMR status -&gt;factorial design?
]
???
the use of PD-L1 as a predictive biomarker to identify those patients who are most likely to benefit from ICI treatment remains difficult due to different assays used for each therapeutic, difference in threshold cutoffs across indications, tumor heterogeneity within and across patient populations, the diversity of patients’ treatment history, and the dynamic status of the tumor microenvironment. Perhaps a single-parameter biomarker (e.g., PD-L1) may not be sufficient to accurately stratify patients for ICI therapy...
I believe we need a collaboration like the BLUEPRINT project in NSCLC; a combination of academia and industry to focus on EC and PD-L1

---
class: sydney-red
background-image: url(assets/USydLogo-white.svg),url(https://upload.wikimedia.org/wikipedia/commons/b/be/Sharingan_triple.svg)
background-size: 260px,100px
background-position: 5% 95%,4% 70%

# Thanks!

.pull-right[.pull-down[

&lt;a href="mailto:kristy.robledo@sydney.edu.au"&gt;
.white[&lt;svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M440 6.5L24 246.4c-34.4 19.9-31.1 70.8 5.7 85.9L144 379.6V464c0 46.4 59.2 65.5 86.6 28.6l43.8-59.1 111.9 46.2c5.9 2.4 12.1 3.6 18.3 3.6 8.2 0 16.3-2.1 23.6-6.2 12.8-7.2 21.6-20 23.9-34.5l59.4-387.2c6.1-40.1-36.9-68.8-71.5-48.9zM192 464v-64.6l36.6 15.1L192 464zm212.6-28.7l-153.8-63.5L391 169.5c10.7-15.5-9.5-33.5-23.7-21.2L155.8 332.6 48 288 464 48l-59.4 387.3z"&gt;&lt;/path&gt;&lt;/svg&gt; kristy.robledo@sydney.edu.au]
&lt;/a&gt;

&lt;a href="https://kristyrobledo.github.io/GCIG-EC/"&gt;
.white[&lt;svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M326.612 185.391c59.747 59.809 58.927 155.698.36 214.59-.11.12-.24.25-.36.37l-67.2 67.2c-59.27 59.27-155.699 59.262-214.96 0-59.27-59.26-59.27-155.7 0-214.96l37.106-37.106c9.84-9.84 26.786-3.3 27.294 10.606.648 17.722 3.826 35.527 9.69 52.721 1.986 5.822.567 12.262-3.783 16.612l-13.087 13.087c-28.026 28.026-28.905 73.66-1.155 101.96 28.024 28.579 74.086 28.749 102.325.51l67.2-67.19c28.191-28.191 28.073-73.757 0-101.83-3.701-3.694-7.429-6.564-10.341-8.569a16.037 16.037 0 0 1-6.947-12.606c-.396-10.567 3.348-21.456 11.698-29.806l21.054-21.055c5.521-5.521 14.182-6.199 20.584-1.731a152.482 152.482 0 0 1 20.522 17.197zM467.547 44.449c-59.261-59.262-155.69-59.27-214.96 0l-67.2 67.2c-.12.12-.25.25-.36.37-58.566 58.892-59.387 154.781.36 214.59a152.454 152.454 0 0 0 20.521 17.196c6.402 4.468 15.064 3.789 20.584-1.731l21.054-21.055c8.35-8.35 12.094-19.239 11.698-29.806a16.037 16.037 0 0 0-6.947-12.606c-2.912-2.005-6.64-4.875-10.341-8.569-28.073-28.073-28.191-73.639 0-101.83l67.2-67.19c28.239-28.239 74.3-28.069 102.325.51 27.75 28.3 26.872 73.934-1.155 101.96l-13.087 13.087c-4.35 4.35-5.769 10.79-3.783 16.612 5.864 17.194 9.042 34.999 9.69 52.721.509 13.906 17.454 20.446 27.294 10.606l37.106-37.106c59.271-59.259 59.271-155.699.001-214.959z"&gt;&lt;/path&gt;&lt;/svg&gt; kristyrobledo.github.io/GCIG-EC/]
&lt;/a&gt;

&lt;a href="http://twitter.com/kristyrobledo"&gt;
.white[&lt;svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M459.37 151.716c.325 4.548.325 9.097.325 13.645 0 138.72-105.583 298.558-298.558 298.558-59.452 0-114.68-17.219-161.137-47.106 8.447.974 16.568 1.299 25.34 1.299 49.055 0 94.213-16.568 130.274-44.832-46.132-.975-84.792-31.188-98.112-72.772 6.498.974 12.995 1.624 19.818 1.624 9.421 0 18.843-1.3 27.614-3.573-48.081-9.747-84.143-51.98-84.143-102.985v-1.299c13.969 7.797 30.214 12.67 47.431 13.319-28.264-18.843-46.781-51.005-46.781-87.391 0-19.492 5.197-37.36 14.294-52.954 51.655 63.675 129.3 105.258 216.365 109.807-1.624-7.797-2.599-15.918-2.599-24.04 0-57.828 46.782-104.934 104.934-104.934 30.213 0 57.502 12.67 76.67 33.137 23.715-4.548 46.456-13.32 66.599-25.34-7.798 24.366-24.366 44.833-46.132 57.827 21.117-2.273 41.584-8.122 60.426-16.243-14.292 20.791-32.161 39.308-52.628 54.253z"&gt;&lt;/path&gt;&lt;/svg&gt; @kristyrobledo]
&lt;/a&gt;

&lt;a href="http://github.com/kristyrobledo"&gt;
.white[&lt;svg viewBox="0 0 496 512" style="height:1em;position:relative;display:inline-block;top:.1em;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"&gt;&lt;/path&gt;&lt;/svg&gt; @kristyrobledo]
&lt;/a&gt;

&lt;br&gt;&lt;br&gt;&lt;br&gt;
]]

???
sharingan
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script src="assets/remark-zoom.js"></script>
<script src="https://platform.twitter.com/widgets.js"></script>
<script>var slideshow = remark.create({
"highlightStyle": "github",
"highlightLines": true,
"countIncrementalSlides": false,
"ratio": "16:9",
"navigation": {
"scroll": false
}
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
// add `data-at-shortcutkeys` attribute to <body> to resolve conflicts with JAWS
// screen reader (see PR #262)
(function(d) {
  let res = {};
  d.querySelectorAll('.remark-help-content table tr').forEach(tr => {
    const t = tr.querySelector('td:nth-child(2)').innerText;
    tr.querySelectorAll('td:first-child .key').forEach(key => {
      const k = key.innerText;
      if (/^[a-z]$/.test(k)) res[k] = t;  // must be a single letter (key)
    });
  });
  d.body.setAttribute('data-at-shortcutkeys', JSON.stringify(res));
})(document);
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
